|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase III, Multicenter, Randomized, Open Label, Clinical study To evaluate Efficacy and Safety of two strengths of Meropenem Plus Tazobactam For the Treatment of Patients with Gram Negative Infection Including Pseudomonas aeruginosa
100 Clinical Results associated with Aqua Vitoe Laboratories
0 Patents (Medical) associated with Aqua Vitoe Laboratories
100 Deals associated with Aqua Vitoe Laboratories
100 Translational Medicine associated with Aqua Vitoe Laboratories